LivingGLP1
Descriptive only

Systolic blood pressure change

Overweight or obesity without diabetes (adults)

weeks 20 to 40 (target week 26)Treatment policyEach dose separatelyMean difference
1
Randomized trials
6
Treatments
340
Participants
6
Trial arms

In plain language

No network meta-analysis was fitted here. The protocol requires at least two trials forming a connected network; this outcome has 1 trial. The trial data below are shown as reported.

Network of trials

Each circle is a treatment; each line joins treatments that were randomized against each other in at least one trial.
BOFANG_SC_12MG_Q2WBOFANG_SC_18MG_Q2WBOFANG_SC_24MG_Q2WBOFANG_SC_24MG_QWBOFANG_SC_48MG_Q2WPLACEBO
Node area shows participants; line width shows trials comparing two treatments directly. Blue: GLP-1 receptor agonist containing treatments; grey: comparators. Hover over or tab to a node or line for details.

Baseline characteristics of the trials

The baseline value of each effect modifier or prognostic factor that applies here, per trial: mean or percent over arms, weighted by the number randomized. A note under a value names a stand in (a median for a mean, 100 minus the male share, Asian subgroup rows, an all Asian site list); "not reported" means no source of the trial prints it.
Baseline effect modifiers and prognostic factors per trial
TrialBaseline BMI or body weight (kg/m2)
effect modifier, prognostic factor; 1 of 1
NCT06256562
S002790
33.23

Comparability of the trials

Checked across designs (the set of treatments each trial compares) for eligibility, outcome definition and assessment, and the baseline factors above. Flags point to possible intransitivity; notes describe variation that is not tied to design.

No comparability concerns were found.

Comparability items per trial
Trialtime weeksanalysis setdefinitioninstrumentadjudicatedproportion methodintercurrent events (discontinuation)intercurrent events (rescue)blindingfundingstart yearEligibility
NCT0625656230modified_ittnot statednot statednot statednot statednot statednot stateddouble_blindindustry2023age 18 to 75; BMI 24 to <28 kg/m2 with comorbidity or 28 or more (Chinese criteria); no diabetes

Trial data

What each trial contributes. Arm rows give the arm value with its standard error, or events over participants; contrast rows give the mean difference on the analysis scale against the trial's first row. Flags mark converted, combined or approximated inputs.
Trial data entering this analysis
TrialArmTreatmentWeekDataValueSEEvents / NFlagsSource
NCT06256562A1BOFANG_SC_12MG_Q2W30arm, change-3.4201.56052R0002409:Supplement Table S4
NCT06256562A2BOFANG_SC_18MG_Q2W30arm, change-8.1301.51053R0002409:Supplement Table S4
NCT06256562A3BOFANG_SC_24MG_Q2W30arm, change-4.8201.58052R0002409:Supplement Table S4
NCT06256562A4BOFANG_SC_48MG_Q2W30arm, change-10.1601.54064R0002409:Supplement Table S4
NCT06256562A5BOFANG_SC_24MG_QW30arm, change-6.9501.64053R0002409:Supplement Table S4
NCT06256562A6PLACEBO30arm, change-0.1001.54066R0002409:Supplement Table S4

Rerun this analysis yourself

Remove treatments or trials and refit the frequentist and Bayesian models in your browser, with the same methods as the published analysis.

Open in the NMA lab